peptides
Semaglutide 20mg
A higher-mass Semaglutide vial for extended research arcs — same GLP-1 receptor agonism studied for appetite, glycemic control, and sustained weight reduction, with fewer reconstitutions per study window.
Research-observed benefits
- ›Appetite suppression
- ›Glycemic control
- ›Sustained weight loss
- ›Cardiometabolic markers
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
Reconstitution helper
Suggested: 3 mL BAC water → 6.67 mg/mL
CAS Number
—
Purity
—
Molecular Formula
—
Stock
500 units
Order type
Quantity
Research-use pricing is provided by request. with the compound name and quantity, or call 714-856-4341 for a written quote.
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
Semaglutide 20mg — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Long-acting GLP-1 receptor agonist. Slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon, and acts centrally on appetite centers.
How It Helps
The most-studied GLP-1 analog — drives appetite reduction, glycemic improvement, and sustained weight loss in research models.
Half-Life
~165 hours (~7 days); once-weekly dosing.
Onset of Effects
Appetite changes within days; weight effects compound over weeks 4–24.
Administration
Subcutaneous, abdomen/thigh/upper arm.
Storage
Lyophilized frozen; reconstituted refrigerated, 28 days.
Reconstitution Guide
10 mg + 2 mL BAC → 5 mg/mL (typical 0.25 mg dose = 0.05 mL).
Precise Dosing Protocols
STEP-protocol titration
- Dose:
- 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly
- Frequency:
- Once weekly SC
- Duration:
- 16-week titration + maintenance
- Notes:
- Increase every 4 weeks if tolerated
Stacks Well With
- ›MOTS-c
- ›Tesamorelin (lean preservation during loss)
- ›NAD+
Research-Observed Side Effects
- •Nausea (titration)
- •GI changes
- •Mild fatigue early
- •Rare gallbladder events in human data
Translational Cautions
- •Personal/family MTC, MEN2 history in human translation
- •Active pancreatitis
Cycling Guidance
Long-term study arcs; tapering is preferred over abrupt discontinuation to avoid rebound appetite.
Research Highlights
- ▸STEP-1 trial: ~14.9% body weight reduction at 68 weeks.
- ▸Significant HbA1c reductions across diabetic cohorts.